
The smoke had barely lifted from the New Year fireworks when Novo Holdings announced its first acquisition of 2022 – US company Medical Knowledge Group (MKG).
The firm, which is based in New York and was founded in 2004, has developed a new platform to launch new drugs, and Managing Partner at Novo Holdings Christoffer Søderberg says that this is very interesting in a time when commercializing new drugs is becoming more and more complex.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.